TCGA-CN-5356-01A-01R-1436-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.570
- UNFOLDED_PROTEIN_RESPONSE+0.390
- MYC_TARGETS_V1+0.310
- HEDGEHOG_SIGNALING+0.290
- UV_RESPONSE_DN+0.270
- MITOTIC_SPINDLE+0.240
- WNT_BETA_CATENIN_SIGNALING+0.210
- APICAL_JUNCTION+0.200
- G2M_CHECKPOINT+0.170
- PI3K_AKT_MTOR_SIGNALING+0.160
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.630
- INTERFERON_GAMMA_RESPONSE-0.500
- OXIDATIVE_PHOSPHORYLATION-0.380
- MYOGENESIS-0.360
- TNFA_SIGNALING_VIA_NFKB-0.360
- HYPOXIA-0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
- IL6_JAK_STAT3_SIGNALING-0.280
- COMPLEMENT-0.270
- INFLAMMATORY_RESPONSE-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 53bd217b-0458-4315-a13c-f9e79fa46501 | — | — | 0.809 |
| 2 | SJEPD031102_D1.RNA-Seq | EPN | Supratentorial EPN | 0.791 |
| 3 | MDT-AP-0194 | Med | Medulloblastoma | 0.786 |
| 4 | 2bd9ef82-12dc-4dcb-8a2c-c58cdf463116 | — | — | 0.785 |
| 5 | 4549956C-8D25-4B37-894C-E82D5C7684F0 | — | — | 0.784 |
| 6 | TCGA-E9-A1N9-01A-11R-A14D-07 | — | C | 0.781 |
| 7 | TCGA-50-6591-01A-11R-1755-07 | — | cohortMD1 | 0.778 |
| 8 | TCGA-34-5927-01A-11R-1820-07 | — | cohortSQ1 | 0.777 |
| 9 | ERR2598213 | fetal | fetal | 0.775 |
| 10 | MDT-AP-0351 | Med | Medulloblastoma | 0.773 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.570 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.390 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.170 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.160 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.050 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.040 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.040 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.020 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.020 | Remibrutinib | — uncovered |